APA (7th ed.) Citation

A, N., B, K., J, K., S, G., D, P., D, C., . . . S, B. (2025). Bioequivalent Letermovir Usage for Prophylaxis in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India. Cureus, 17(4), e83035. https://doi.org/10.7759/cureus.83035

Chicago Style (17th ed.) Citation

A, Nag, et al. "Bioequivalent Letermovir Usage for Prophylaxis in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India." Cureus 17, no. 4 (2025): e83035. https://doi.org/10.7759/cureus.83035.

MLA (9th ed.) Citation

A, Nag, et al. "Bioequivalent Letermovir Usage for Prophylaxis in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India." Cureus, vol. 17, no. 4, 2025, p. e83035, https://doi.org/10.7759/cureus.83035.